Yukihiko Kato

ORCID: 0000-0002-1110-9533
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Histone Deacetylase Inhibitors Research
  • Cutaneous lymphoproliferative disorders research
  • Dermatology and Skin Diseases
  • Cancer and Skin Lesions
  • Caveolin-1 and cellular processes
  • Peripheral Neuropathies and Disorders
  • Protein Degradation and Inhibitors
  • Allergic Rhinitis and Sensitization
  • Lymphoma Diagnosis and Treatment
  • Systemic Lupus Erythematosus Research
  • Vascular Tumors and Angiosarcomas
  • Retinoids in leukemia and cellular processes
  • Mechanisms of cancer metastasis
  • Contact Dermatitis and Allergies
  • Cancer Mechanisms and Therapy
  • Carcinogens and Genotoxicity Assessment
  • Melanoma and MAPK Pathways
  • Ubiquitin and proteasome pathways
  • Toxic Organic Pollutants Impact
  • Nail Diseases and Treatments
  • Nonmelanoma Skin Cancer Studies
  • Cell Adhesion Molecules Research
  • Drug-Induced Ocular Toxicity
  • Cancer, Hypoxia, and Metabolism
  • Estrogen and related hormone effects

Tokyo Medical University Hachioji Medical Center
2017-2025

Tokyo Medical University
2002-2022

Tokyo Metropolitan Tama Medical Center
2012-2022

Fujita Health University
1988-2022

X-Fab (Germany)
2018

Tokyo Medical University Hospital
2003-2013

Seirei Hamamatsu General Hospital
2011-2012

Kanazawa University
2012

Canon (Japan)
1988-2010

Sidney Kimmel Comprehensive Cancer Center
2004-2009

Abstract Purpose: Angiogenesis is required for tumor progression and represents a rational target therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to activity against various cell types by inhibiting proliferation inducing apoptosis both in vitro vivo. HDAC also reported inhibit angiogenesis. The goal of this study was characterize the antiangiogenic antitumor recently developed inhibitor, hydroxamic derivative LBH589. Materials Methods: To evaluate...

10.1158/1078-0432.ccr-05-1132 article EN Clinical Cancer Research 2006-01-15

Chromatin remodeling agents such as histone deacetylase inhibitors have been shown to modulate gene expression in tumor cells and inhibit growth angiogenesis. Vascular endothelial factor (VEGF) VEGF receptors represent critical molecular targets for antiangiogenesis therapy. In this study, we investigated the biological effect of inhibitor NVP-LAQ824 combination with receptor tyrosine kinase PTK787/ZK222584 on We report that treatment affected was associated increased acetylation, p21...

10.1158/0008-5472.can-04-0540 article EN Cancer Research 2004-09-15

ABSTRACT The lipophilic yeast Malassezia globosa is one of the major constituents mycoflora skin patients with atopic dermatitis (AD). We compared genotypes M. colonizing surface 32 AD and 20 healthy individuals for polymorphism intergenic spacer (IGS) 1 region rRNA gene. Sequence analysis demonstrated that was divided into four groups, which corresponded to sources samples, on phylogenetic tree. Of two were from subjects. remaining group included samples both In addition, IGS contained...

10.1128/jcm.41.7.3022-3027.2003 article EN Journal of Clinical Microbiology 2003-07-01

Abstract Purpose: High-dose interleukin 2 (IL-2) is a Food and Drug Administration–approved regimen for patients with metastatic renal cell carcinoma. However, the toxicity limited clinical benefit associated IL-2 has hampered its use. Histone deacetylase (HDAC) inhibitors have been shown to antitumor activity in different tumor models including carcinoma, immunomodulatory properties. In our study, we tested effectiveness of combination therapy HDAC inhibitor MS-275 murine carcinoma (RENCA)...

10.1158/1078-0432.ccr-07-0014 article EN Clinical Cancer Research 2007-08-01

Abstract Cancers display distinct patterns of organ-specific metastasis. Comparative analysis a broad array cell membrane molecules on liver-metastasizing subline B16 melanoma versus the parental B16-F0 revealed unique up-regulation integrin α2. The direct role α2 in hepatic metastasis was shown by comparison high low-expressing populations, antibody blockade, and ectopic expression. Integrin α2–mediated binding to collagen type IV (highly exposed liver sinusoids) IV–dependent activation...

10.1158/0008-5472.can-09-0315 article EN Cancer Research 2009-09-09

Abstract The concept of immune reconstitution inflammatory syndrome (IRIS) has recently been applied to patients with non‐HIV infection fluctuations. However, quantitative criteria diagnose IRIS have not established. Similarly, immune‐related adverse events (irAEs) caused by checkpoint inhibitors (ICIs) are also No study directly compared the immunological indicators and irAEs. Thus, we investigated whether irAEs can be included in IRIS. We aimed search for diagnostic biomarkers compare...

10.1111/1346-8138.17706 article EN The Journal of Dermatology 2025-03-29

Histone deacetylase (HDAC) inhibitors have been shown to reverse epigenetic repression of certain genes, including retinoic acid receptor beta2 (RARbeta2). In this study, we examined whether RARbeta2 expression is repressed in human renal cell carcinoma (RCC) and the HDAC inhibitor MS-275 may revert its repression.Six tumor RCC lines were analyzed for gene methylation acetylation status at promoter level. Modulation correlation with antitumor activity by combination 13-cis-retinoic (CRA) was...

10.1158/1078-0432.ccr-04-1092 article EN Clinical Cancer Research 2005-05-01

Abstract Resistance to chemotherapy is a major hurdle in the treatment of malignant melanoma. Histone deacetylase (HDAC) inhibitors have been shown antitumor activity different tumor types, including melanoma, and reverse epigenetic repression suppressor genes, such as retinoic acid receptor β (RARβ). In this study, we tested effect HDAC inhibitor LAQ824 combination with 13-cis-retinoic (CRA) on two human melanoma cell lines both vitro vivo. Treatment showed dose-dependent inhibitory A2058...

10.1158/1535-7163.mct-06-0125 article EN Molecular Cancer Therapeutics 2007-01-01

Abstract BACKGROUND Histone deacetylase (HDAC) inhibitors represent a novel class of therapeutic agents with antitumor activity currently in clinical development. In this study, we tested the biological effects HDAC inhibitor MS‐275 various pre‐clinical prostate cancer models both in'vitro and vivo. METHODS vitro cell proliferation XTT assay protein expression analysis by Western blot were performed. vivo tumor growth assessment subcutaneous, orthotopic, transgenic mouse conducted. RESULTS...

10.1002/pros.20611 article EN The Prostate 2007-05-22

Background Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ Japanese patients with lupus-related skin disease using cutaneous lupus erythematosus area and severity index (CLASI). Methods Twenty-seven who started at four hospitals were included. Patients categorized into responders by CLASI criteria. The points rate improvement activity score after 16 weeks treatment analyzed, focusing on six parameters: systemic (SLE),...

10.3109/s10165-012-0656-3 article EN Modern Rheumatology 2013-03-01

Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ Japanese patients with lupus-related skin disease using cutaneous lupus erythematosus area and severity index (CLASI).Twenty-seven who started at four hospitals were included. Patients categorized into responders by CLASI criteria. The points rate improvement activity score after 16 weeks treatment analyzed, focusing on six parameters: systemic (SLE), manifestations,...

10.1007/s10165-012-0656-3 article EN Modern Rheumatology 2012-05-11

Malignant melanoma cells have been reported to be highly resistant chemotherapeutic agents. To gain insight into the molecular mechanisms underlying drug resistance, we examined role of Bcl-2 family members and Bax in cell death line G361 following stimulation with cisplatin (CDDP) or dacarbazine (DTIC). Trypan blue dye exclusion showed that both CDDP DTIC induced cells. Apoptotic necrotic could distinguished by flow cytometry using combined staining annexin V 7-amino-actinomycin D (7-AAD)....

10.1097/00008390-200310000-00004 article EN Melanoma Research 2003-09-26

Abstract A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T‐cell lymphoma (CTCL). Six received (400 mg p.o., once daily). Dose‐limiting toxicities (DLT) were evaluated all six during 28 days first cycle. One who developed a DLT (grade 4 thrombocytopenia). The most common drug‐related adverse events included nausea (4/6, 67%),...

10.1111/j.1346-8138.2012.01554.x article EN The Journal of Dermatology 2012-04-16

Intravascular large B-cell lymphoma (IVL) is a rare subtype of extranodal malignant lymphoma. The proliferation neoplastic B cells within small blood vessels causes eruptions and other symptoms in variety organs. random skin biopsy useful for diagnosing this condition its early stages. In order to assess the diagnostic utility method, we examined 3 cases with aim comparing occurrence tumor lesional healthy-looking by performing 32 separate sites. Our findings from total specimens collected...

10.1159/000437363 article EN Dermatology 2016-01-01

Abstract Our previous research showed that lipophilic yeasts, Malassezia species, colonize the skin of patients with atopic dermatitis (AD) at a high frequency. In this study, we found two basidiomycetous Cryptococcus diffluens and C. liquefaciens , significantly more frequently in AD than healthy subjects. Transparent dressings were applied to 36 30 subjects then transferred onto Sabouraud dextrose agar. Colonies recovered from medium identified by DNA sequence analysis internal transcribed...

10.1111/j.1348-0421.2003.tb03468.x article EN Microbiology and Immunology 2003-12-01

Malignant peripheral nerve sheath tumors (MPNST) constitute a rare variety of soft tissue sarcomas thought to originate from Schwann cells or pluripotent the neural crest. triton tumor (MTT), very rare, highly aggressive tumor, is subgroup MPNST and comprised malignant coexisting with rhabdomyoblasts. We herein report case 24-year-old man who presented subcutaneous mass in his right thigh. The was removed surgically its entirety radiation therapy applied locally prevent regrowth....

10.1159/000357610 article EN cc-by-nc Case Reports in Dermatology 2013-12-24

We evaluated the cutaneous lupus erythematosus disease area and severity index (CLASI) in Japanese patients with systemic (SLE) order to design a clinical trial of hydroxychloroquine (HCQ) Japan. Our prospective cohort study consisted seven SLE active skin who started HCQ at Tokyo Metropolitan Tama Medical Center. The therapeutic responses were assessed 4 months. Patients categorized as responders (improved) or non-responders (unchanged worsened) using criteria 4-point 20% decrease CLASI...

10.1007/s10165-011-0503-y article EN Modern Rheumatology 2011-08-13

Ingesting certain foods sometimes triggers anaphylaxis when followed by exercise (food-dependent exercise-induced anaphylaxis, FDEIA). Specific food-induced mucocutaneous urticaria may also progress to (oral allergy syndrome, OAS). A positive skin test and/or radioallergosorbent (RAST) the suggest involvement of immunoglobulin (Ig)E-anaphylaxis in both disorders. The triggering and initial target organs are usually different each case. In present study, a 32-year-old male reported dyspnea...

10.1111/j.1346-8138.2006.00227.x article EN The Journal of Dermatology 2007-01-16

The Non-genotoxic Carcinogen Study Group in the Environmental Mutagen Society of Japan organised second step inter-laboratory collaborative study on one-stage and two-stage cell transformation assays employing BALB/c 3T3 cells, with objective confirming whether respective laboratories could independently produce results relevant to initiation or promotion. method was modified use a medium consisting DMEM/F12 supplemented 2% fetal bovine serum mixture insulin, transferrin, ethanolamine sodium...

10.1177/026119291003800111 article EN Alternatives to Laboratory Animals 2010-03-01
Coming Soon ...